[go: up one dir, main page]

MX2018001905A - Metodos para el tratamiento del virus de hepatitis c (vhc). - Google Patents

Metodos para el tratamiento del virus de hepatitis c (vhc).

Info

Publication number
MX2018001905A
MX2018001905A MX2018001905A MX2018001905A MX2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A
Authority
MX
Mexico
Prior art keywords
treatment
methods
weeks
compound
pharmaceutically acceptable
Prior art date
Application number
MX2018001905A
Other languages
English (en)
Inventor
M Awni Walid
Liu Wei
M Bernstein Barry
J Podsadecki Thomas
Dutta Sandeep
M Menon Rajeev
Wang Tianli
Mensing Sven
L Campbell Andrew
Wei LIN Chih-
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,906 external-priority patent/US11484534B2/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018001905A publication Critical patent/MX2018001905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención presenta terapias exentas de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es a lo largo de una duración más corta de tratamiento, tal como no mayor de 12 semanas. En un aspecto, el tratamiento comprende la administración de al menos dos agentes antivíricos de acción directa a un sujeto con infección por el VHC, en donde el tratamiento tiene una duración de 12 semanas y no incluye la administración de interferón o de ribavirina, y dichos al menos dos agentes antivíricos de acción directa comprenden (a) el compuesto 1 o una de sus sales farmacéuticamente aceptables y (b) el compuesto 2 o una de sus sales farmacéuticamente aceptables.
MX2018001905A 2017-02-14 2018-02-14 Metodos para el tratamiento del virus de hepatitis c (vhc). MX2018001905A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/431,906 US11484534B2 (en) 2013-03-14 2017-02-14 Methods for treating HCV

Publications (1)

Publication Number Publication Date
MX2018001905A true MX2018001905A (es) 2018-11-09

Family

ID=61192811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001905A MX2018001905A (es) 2017-02-14 2018-02-14 Metodos para el tratamiento del virus de hepatitis c (vhc).

Country Status (7)

Country Link
EP (1) EP3360555A1 (es)
JP (1) JP2018131439A (es)
CN (1) CN108421029A (es)
AU (1) AU2018201011A1 (es)
BR (1) BR102018002956A2 (es)
CA (1) CA2994496A1 (es)
MX (1) MX2018001905A (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549167A1 (en) * 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
EA201490837A1 (ru) * 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
SI3213750T1 (sl) * 2013-03-14 2020-11-30 Abbvie Inc. Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
ES2654109T3 (es) * 2013-03-14 2018-02-12 Abbvie Inc. Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC
CN110302361A (zh) * 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法
CN107921038A (zh) * 2015-07-08 2018-04-17 艾伯维公司 用于治疗hcv 的方法

Also Published As

Publication number Publication date
AU2018201011A1 (en) 2018-08-30
BR102018002956A2 (pt) 2018-10-30
JP2018131439A (ja) 2018-08-23
EP3360555A1 (en) 2018-08-15
CA2994496A1 (en) 2018-08-14
CN108421029A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX388482B (es) Métodos para tratar el virus de la hepatitis c.
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2018000240A (es) Metodos para tratar el vhc.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12014500833A1 (en) Methods for treating hcv
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
RU2015114543A (ru) Способы лечения гепатита с
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
MX2021002147A (es) Tratamiento de la infección por virus de la hepatitis delta con interferón lambda.
RU2015114566A (ru) Способы лечения гепатита с
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
UA101772U (uk) Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки
RU2008142658A (ru) Способ лечения инфекционных поражений нервной системы